Articles
Insights from a CCO: Evolving oncology market dynamics and expediting therapy to metastatic HER2-positive breast cancer patients
Posted on February 16, 20222/16/22
Oncology Chief Commercialization Officer, Suzanne Greenwood, shares insights on evolving oncology market dynamics and expediting therapy to metastatic HER2-positive breast cancer patients Watch the full 60-minute virtual panel, “Next Gen Commercial Models in Oncology,” PharmaVOICE Editor Taren Grom…
A scorecard for osteoporosis in Canada and seven Canadian provinces
- Journal/Conference:
- Osteoporosis International
- Author(s):
- DL Kendler, JD Adachi, JP Brown, AG Juby, CS Kovacs, C Duperrouzel, RK McTavish, C Cameron, L Slatkovska, N Burke
- Publication Date:
- 2021
- Topic/Therapeutic Area:
- Skeletal
Indirect comparisons of siponimod with fingolimod and ofatumumab in multiple sclerosis: assessing the feasibility of propensity score matching analyses
- Journal/Conference:
- Current Medical Research and Opinion
- Author(s):
- Samjoo IA, Worthington E, Haltner A, Spin P, Drudge C, Cameron C, Brennan R, Dahlke F, Adlard N
- Publication Date:
- 2021
- Topic/Therapeutic Area:
- Multiple Sclerosis, Nervous System
Using Survey Research to Develop Payer Strategies for an Existing Biologic’s Unique Indication in a Highly Competitive Market
Posted on November 29, 202111/29/21
How Pre-Launch Financial Exposure Modeling and Planning Can Help a Biopharmaceutical Reach More Patients
Posted on November 29, 202111/29/21
Developing a Channel Strategy Through Benchmarking For a First-in-Class Product Portfolio
Posted on November 29, 202111/29/21
European Guidelines and Real-World Evidence of Maintenance Treatments for Adults with Acute Myeloid Leukemia in First Complete Remission.
- Journal/Conference:
- European Hematology Association Annual Meeting
- Author(s):
- Ahmed M, Thompson G, Martin C, Cameron H, Chen C
- Publication Date:
- 2021
- Topic/Therapeutic Area:
- Oncology
Matching Adjusted Indirect Comparison (MAIC) of Oral Azacitidine (Oral-AZA) Versus Injectable AZA in Patients (pts) with Acute Myeloid Leukemia (AML) in First Remission after Intensive Induction Chemotherapy.
- Journal/Conference:
- Blood 138 (Supplement 1): 3015
- Author(s):
- Chen, C.; Huls, GA.; Cameron, H.; Suero, B.; Vasconcelos A.; Gaugler, L.; Beach, C.L.
- Publication Date:
- 2021
- Topic/Therapeutic Area:
- Oncology